Pure Global AI: A Practical Workflow Guide for Medical Device Regulatory Teams
A vendor-neutral guide to Pure Global AI's regulatory databases, device and predicate agents, and evidence-first workpapers for risk, eSTAR, CAPA, QMSR, labeling, and post-market review.
Medical device regulatory, quality, clinical, and market-access teams face a persistent operational headache: regulatory intelligence is scattered across dozens of disconnected national databases, paid subscription portals, language barriers, and static PDF guidance documents. When evaluating a new market, identifying predicate devices, or preparing quality system audits, professionals often waste days manually toggling between regulator websites.
Pure Global AI addresses this bottleneck by providing a free, open data layer that brings together 37 national medical-device registries, FDA datasets, clinical trials across 40 countries, regulations, timelines, government fees, and evidence-first AI workpapers in one web platform. It is built by Pure Global to support early regulatory research, market comparison, submission preparation, and lifecycle evidence review.
However, using a third-party regulatory intelligence aggregator requires clear protocols. Pure Global AI is a discovery and triage layer—it does not replace official national registries, licensed standards organizations, or certified regulatory counsel.
This practical guide breaks down what the free platform offers, provides a task-to-tool decision table, details a five-stage market-access and evidence-review workflow, demonstrates primary-source verification against official FDA datasets, and outlines the boundaries between free AI workpapers, controlled QMS records, and paid consulting services.
What is Pure Global AI and What Does the Free Platform Include?
Pure Global AI is an open suite of medical-device regulatory tools hosted at pureglobal.ai/resources. Its current catalog spans four functional groups:
Data & Research Databases: Searchable interfaces mirroring official device registration listings, product codes, premarket notifications, adverse events, clinical trial registries, and national regulations.
Planning & Comparison Tools: Country-by-country matrices covering official government fees, registration lead times, and local representation rules across ~30 major MedTech markets.
AI Research Utilities: A 37-country device classifier, a multi-country similar-product finder, and an FDA predicate and pathway agent that search retrieved registration or FDA records.
Evidence-First Workpapers: Structured reviews for risk-management files, FDA eSTAR readiness, CAPA investigations, complaint reportability and FSCA, FDA QMSR implementation, labels and IFUs, and PMS/PMCF/clinical evidence.
+-----------------------------------------------------------------------------------+
| PURE GLOBAL AI OPEN DATA LAYER |
+------------------------------------+----------------------------------------------+
| DATA & RESEARCH | PLANNING & COMPARISON |
| • 37 National Device Registries | • Registration Timelines (~30 Countries) |
| • FDA Datasets (510k, PMA, MAUDE) | • Government Fee Schedules (31 Countries) |
| • 40-Country Clinical Trials | • Country Comparison Matrix |
| • 38-Country Regulations Library | • Global Rep & License Holder Rules |
+------------------------------------+----------------------------------------------+
| AI RESEARCH & EVIDENCE WORKPAPERS |
| • 37-Country Device Classifier • Similar Product Finder |
| • FDA Predicate & Pathway Agent • Risk, eSTAR, CAPA & QMSR Reviews |
| • GSPR / ISO 13485 / MDSAP • Label/IFU & PMS/PMCF/CER Reviews |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| PRIMARY-SOURCE VERIFICATION LAYER |
| Official Registries: openFDA | EUDAMED | NMPA | PMDA | ANVISA | ClinicalTrials.gov |
+-----------------------------------------------------------------------------------+Coverage Scope and Headline Registries
According to Pure Global's published data methodology, the platform indexes over 1.9 million device registration records globally. However, record counts vary significantly by country depending on whether national databases report individual device models, master family approvals, or establishment listings:
| Country / Region | Primary Regulator / Source | Reported Record Volume | Primary Data Fields Mirrored |
|---|---|---|---|
| Thailand | Thai FDA | 4,400,000+ | Device registrations, import licenses |
| European Union | EUDAMED / National Registries | 563,000+ | Public UDI/device listings, CE certificates |
| South Korea | MFDS (Ministry of Food & Drug Safety) | 314,000+ | Item approvals, classification codes |
| United Kingdom | MHRA Public Register | 150,962+ | Registered devices, GMDN/EMDN terms |
| China | NMPA (National Medical Products Admin) | 149,000+ | Domestic & imported device registrations |
| United States | U.S. FDA Datasets | 120,000+ | 510(k), PMA, De Novo, GUDID/UDI, Establishments |
| Brazil | ANVISA | 109,598+ | Device registrations (registros & notificações) |
| Japan | PMDA / MHLW | 88,000+ | Approved medical devices & IVDs |
Note: Raw record counts reflect national database structures and cannot be used directly as a market-size proxy. For example, Thailand's high record count stems from granular line-item import filings, whereas U.S. FDA 510(k) clearances summarize broader device families.
Task-to-Tool Decision Table for Regulatory Teams
To avoid aimless browsing, regulatory, quality, and clinical professionals should map their immediate objective to the specific tool inside Pure Global AI, while identifying the official source required for final verification:
| Task / Objective | Pure Global AI Tool & Canonical Link | Primary Official Source to Verify | Recommended Deep-Dive Guide |
|---|---|---|---|
| Survey Registered Products and Competitors | Global Device Registration Database Registry Insights | The applicable national device registry | Country registration records and trend exploration |
| Find Similar Devices Across Markets | Global Similar Medical Device Finder | Retrieved records in each selected national registry | Use matches as research leads, not proof of equivalence or classification |
| Determine Device Class & Pathway | AI Device Classifiers FDA Product Code Lookup | FDA Classification Database / EU MDR Annex VIII Rules | vendor-neutral AI regulatory workflow checklist |
| Find Predicate Devices and Pathways | FDA 510(k) Database FDA Predicate & Pathway Agent FDA De Novo Decisions | FDA 510(k), classification, and De Novo records | our complete FDA 510(k) and device-database guide |
| Inspect Safety Signals & Recalls | FDA MAUDE Search FDA Recalls Search | FDA MAUDE and Medical Device Recalls databases | our complete FDA 510(k) and device-database guide |
| Compare Global Timelines & Fees | Registration Timelines Government Fees | National regulator fee schedules and published review targets | Build an indicative market-entry plan before obtaining formal quotes |
| Assess Clinical Trial Landscape | Clinical Trials Database | ClinicalTrials.gov and the applicable national registry | ClinicalTrials.gov device-trials teardown |
| Audit EU MDR GSPR Compliance | EU MDR GSPR Checklist | Regulation (EU) 2017/745 Annex I | GSPR Annex I evidence matrix template |
| Prepare ISO 13485 Internal Audit | ISO 13485 Audit Checklist | Licensed ISO 13485:2016 standard | ISO 13485 internal audit guide |
| Verify MDSAP Audit Readiness | MDSAP Audit Checklist | Current official MDSAP Audit Approach and companion documents | MDSAP audit preparation guide |
| Review Risk-Management Traceability | AI Risk Management File Review | Current risk file, applicable standards, verification evidence, and accountable approvals | Identify risk-control-verification gaps; do not treat the report as risk acceptance |
| Prepare an FDA eSTAR Evidence Index | FDA eSTAR Readiness Review | Current official FDA eSTAR and submission-specific instructions | Find missing sections and attachments; the tool cannot mark an official eSTAR complete |
| Structure a CAPA Investigation | AI CAPA Investigation Builder | Controlled event, investigation, action, and effectiveness records | Separate facts from assumptions and test causal logic; accountable staff approve and close CAPA |
| Screen Complaint Reporting and Field Action Questions | Complaint, Reportability & FSCA Workpaper | Current market rules, complete investigation, health-risk analysis, and local review | Build a chronology and question list; do not use it as the final reportability decision |
| Test FDA QMSR Implementation Evidence | FDA QMSR Evidence Gap Review | Current QMSR, incorporated standards, operating records, and inspection procedures | Look beyond a paper crosswalk; the output does not certify a QMS or predict inspection results |
| Compare Labels and IFUs | AI Medical Device Label & IFU Review | Current market labeling rules, controlled artwork, translation, and human review | Find text inconsistencies and evidence gaps; the tool cannot assess print, prominence, or durability |
| Connect PMS, PMCF, CER, Risk, and CAPA | AI PMS, PMCF & Clinical Evidence Review | Complete lifecycle datasets and controlled CER/PSUR/PMS procedures | Identify disconnected evidence; the output is not a final CER, PSUR, or conformity decision |
| Track National Regulations & News | Regulations Library Regulatory News | National official gazettes and regulator portals | vendor-neutral AI regulatory workflow checklist |
A Five-Stage Market-Access and Evidence-Review Workflow
When expanding a medical device or IVD into new international territories, regulatory teams can combine Pure Global AI's modules into a five-stage workflow. The first three stages search public evidence; the last two organize company evidence for qualified review.
+-----------------------------------------------------------------------------------+
| STEP 1: CLASSIFICATION & PATHWAY SCOPING |
| Enter intended use & tech specs into Pure Global AI Device Classifier & FDA |
| Product Code tool to identify risk class (Class I/IIa/IIb/III or Class 1/2/3). |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| STEP 2: PREDICATE & CLINICAL BENCHMARKING |
| Query Pure Global AI FDA 510(k), PMA & Clinical Trial tools for reference |
| cleared devices, primary endpoints, trial sizes, and adverse event profiles. |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| STEP 3: REGISTRATION TIMELINE & GOVERNMENT FEE BUDGETING |
| Extract indicative lead times and official fees across target markets (US, EU, |
| Japan, Brazil, China) to build executive commercialization roadmaps. |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| STEP 4: QUALITY SYSTEM & TECHNICAL FILE GAP AUDITING |
| Complete interactive GSPR Annex I, ISO 13485, and MDSAP checklists to track |
| mandatory test evidence, risk management files, and QMS SOP preparedness. |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| STEP 5: EVIDENCE-FIRST WORKPAPER REVIEW |
| Paste an authorized, de-identified evidence index into the task-specific agent; |
| resolve gaps inside controlled QMS and submission records after qualified review. |
+-----------------------------------------------------------------------------------+Step 1: Rapid Device Classification & Target Pathway Discovery
Before committing resources to target markets, determine how regulators in the U.S., EU, China, Japan, and Brazil classify your device:
Navigate to the Pure Global AI Device Classifiers.
Input your device's intended purpose, patient contact level, technology type, and operational mechanism.
Review the predicted classification across 37 jurisdictions (e.g., U.S. Class II 510(k) vs EU MDR Class IIa vs China NMPA Class II).
Cross-reference U.S. product codes using the FDA Product Code Lookup to identify the 3-letter product code, regulation number, and medical specialty panel.
Step 2: Predicate Identification & Risk-Profile Scoping
For 510(k) submissions, identifying an appropriate predicate device is essential:
Search the Pure Global AI FDA 510(k) Database by product code, applicant name, or clearance date, or use the FDA Predicate & Pathway Agent for a cross-dataset first pass.
Examine cleared 510(k) decision summaries to inspect statement of intended use, technological characteristics, and bench performance testing.
Check safety histories using the FDA MAUDE Search and FDA Recalls Search for competitor devices to identify questions that require deeper review. Report counts are not incidence rates and do not prove device-event causality.
For clinical strategy, query the Pure Global AI Clinical Trials Database to evaluate study sample sizes, control groups, and primary endpoints used in similar device trials.
Step 3: Registration Timelines, Government Fees & Country Comparison
Market selection requires balancing regulatory complexity against time-to-market and financial cost:
Consult the registration timeline comparison and government fee schedules for indicative benchmarks across major markets.
Separate official government submission fees from third-party costs (such as testing laboratories, authorized representative retainers, notified body audits, and translation fees).
Identify structural prerequisites, such as requiring U.S. FDA 510(k) clearance or an EU CE mark prior to abridged registration in secondary markets (e.g., Singapore HSA, Israel MOH, or Mexico COFEPRIS).
Step 4: Quality System & Technical Documentation Gap Audits
Once target jurisdictions are selected, assemble compliant technical documentation and verify QMS readiness:
EU Market Entry: Use the EU MDR GSPR Checklist to evaluate compliance against General Safety and Performance Requirements (Annex I). Map clinical evaluation reports (CER), software lifecycle files (IEC 62304), and usability studies (IEC 62366) to specific checklist items.
Quality Management Systems: Run the ISO 13485 Audit Checklist to review document control, risk management interfaces, management review, and supplier evaluation evidence.
Multi-Country Quality Audits: Use the MDSAP Audit Checklist to inspect country-specific quality management requirements across the U.S., Canada, Brazil, Japan, and Australia.
Step 5: Route the Evidence Pack to One Task-Specific Workpaper
Select the workpaper by the controlled output under review, not by sending the same product summary to every agent. A submission team might move from the FDA pathway agent to the eSTAR readiness review; a quality team might move from QMSR readiness into risk or CAPA review; a post-market team may connect complaint/FSCA screening with the PMS/PMCF/CER workpaper. Each generated report should become a review aid attached to an internal task—not an automatically approved quality record.
How to Use the New Evidence-First AI Workpapers
The seven workpapers share a useful design principle: they separate supplied facts and documents from plans, assumptions, and unknowns. They also produce a practical gap report rather than claiming to approve a submission or quality decision. Their inputs and limits differ:
| Workpaper | What to Provide | Useful Output | Hard Boundary |
|---|---|---|---|
| Risk Management File Review | Risk plan, hazard analysis/FMEA, controls, verification, residual-risk reasoning, complaints, and post-market signals | Traceability and unsupported-assumption review | Does not establish ISO 14971 conformity or acceptable risk |
| FDA eSTAR Readiness Review | Pathway, device and indications, predicate strategy, testing status, and attachment index | Ready/partial/missing evidence worklist | Does not replace the current FDA dynamic eSTAR or technical screening |
| CAPA Investigation Builder | Event, requirement, containment, investigation evidence, competing causes, actions, owners, and effectiveness criteria | Structured investigation and causal-logic questions | Cannot verify evidence, approve root cause, or close CAPA |
| Complaint, Reportability & FSCA Workpaper | De-identified event chronology, outcome, identifiers, investigation, distribution, risk, CAPA, and markets | Missing-fact, reporting-path, and field-action questions | Cannot make the manufacturer's final reportability decision |
| FDA QMSR Evidence Gap Review | QMS scope, transition crosswalk, audits, management review, supplier, risk, complaint/CAPA, and validation records | Implementation and inspection-readiness gaps | Does not reproduce ISO 13485, certify the QMS, or predict FDA inspection results |
| Label & IFU Review | Intended use, users, markets, all visible label/IFU text, symbols, UDI, claims, and revisions | Internal inconsistencies and market-specific questions | Text-only review cannot approve artwork, translation, prominence, or durability |
| PMS, PMCF & Clinical Evidence Review | PMS plan, complaints, vigilance, literature, PMCF, CER/PSUR, risk changes, and CAPA links | Lifecycle evidence gaps and disconnected conclusions | Cannot establish clinical safety, performance, equivalence, or conformity |
Each page states that Pure Global does not save pasted text or the generated report, but the text is sent to its AI provider for the one-time analysis. Remove patient identifiers, trade secrets, customer-confidential material, and any information your organization is not authorized to transmit. A de-identified evidence index is a sensible first pass; detailed records should be used only under the manufacturer's information-security and QMS controls.
How to Verify Pure Global AI Data Against Official Sources
While Pure Global AI simplifies cross-database queries, regulatory submissions require verifiable primary-source data. Aggregators can experience indexing lag, character encoding shifts, or parsing omissions.
+-----------------------------------------------------------------------------------+
| OFFICIAL SOURCE VERIFICATION PROTOCOL |
+-----------------------------------------------------------------------------------+
| 1. RECORD DISCOVERY |
| Locate potential predicate device or establishment listing on Pure Global AI. |
| Note key parameters: K-number, PMA-number, Product Code, or FEI / Registration. |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| 2. PRIMARY REGISTRY QUERY |
| Navigate directly to the official government database: |
| • FDA: accessdata.fda.gov / openFDA API |
| • EU: EUDAMED public portal (ec.europa.eu/tools/eudamed) |
| • UK: MHRA Public Register |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| 3. ATTRIBUTE DISCREPANCY CHECK |
| Verify critical regulatory fields: |
| [✓] Applicant / Registration Holder Legal Name & Address |
| [✓] Exact Statement of Intended Use & Indications for Use |
| [✓] Active vs Suspended vs Expired Status |
| [✓] UDI-DI / GUDID Primary Device Identifier Matches |
+-----------------------------------------------------------------------------------+
|
v
+-----------------------------------------------------------------------------------+
| 4. CONTROLLED DOCUMENTATION RECORDING |
| Download official PDF decision summary or screenshot stamped registry page. |
| Archive inside QMS Design History File (DHF) / Regulatory Submission Package. |
+-----------------------------------------------------------------------------------+Reproducible Verification Example: FDA Establishment Registrations
To demonstrate primary-source verification, consider verifying U.S. establishment registration listings found via the Pure Global AI FDA Registration & Listing Search.
An analysis of the official openFDA Device Registration & Listing API (snapshot updated March 2026) provides a structural baseline for the official FDA source:
Total Active Device Listing Rows: 336,461 listing entries across the entire database.
Distinct Active Registered Establishments (
status_code = 1): Exactly 27,060 registered medical device facility records.Facility Identifier Alignment: 27,042 distinct Firm Establishment Identifier (FEI) numbers actively maintained in the FDA system.
When inspecting a firm's establishment listing on Pure Global AI, professionals should perform a quick API or manual check against the official FDA record to confirm the legal name, address, listing details, and current registration status before naming the firm as a contract manufacturer or importer in a submission.
Can Free GSPR, ISO 13485, and MDSAP Checklists Support a Real Audit?
Pure Global AI provides free interactive checklists for major regulatory and quality frameworks:
EU MDR GSPR Checklist: Interactive breakdown of Annex I requirements for medical devices.
ISO 13485 Audit Checklist: Clause-level audit readiness tracking for ISO 13485:2016 quality management systems.
MDSAP Audit Checklist: Multi-jurisdictional task matrix based on the Medical Device Single Audit Program audit model.
Utility vs. Audit Compliance Boundaries
It is vital to distinguish between a scoping checklist and a certified Quality Management System audit record:
Scoping & Readiness Triage: Pure Global AI checklists are ideal for initial gap identification, team assignment, and preliminary progress tracking. They allow cross-functional teams to quickly visualize which technical standards or test reports are missing.
Standard Copyright Restrictions: Free online checklists summarize standard requirements; they do not reproduce licensed normative text from ISO standards (such as ISO 13485:2016 or ISO 14971:2019) or official Notified Body audit task lists (such as MDSAP AU P0002.010).
Controlled QMS Execution: Formal internal audits and external audit preparation require controlled records, assigned owners, documented evidence, and approvals under the manufacturer's own QMS procedures.
For comprehensive methodologies on executing formal audits and technical documentation, consult our detailed guides:
For EU technical files, review our GSPR Annex I evidence matrix template.
For QMS internal audits, follow our ISO 13485 internal audit guide.
For multi-country audit prep, refer to our MDSAP audit preparation guide.
Stated Platform Limitations & When to Pay for Expert Consulting
Understanding what a platform cannot do is just as important as knowing its features. In its public data methodology, Pure Global explicitly outlines key operational boundaries:
Platform Data Limitations
Source-of-Truth Lag: Aggregated registry data is updated periodically. Official national registry updates may take days or weeks to reflect on third-party portals.
Field Completeness Variance: Secondary markets often publish limited public fields (e.g., missing device descriptions or redacted manufacturer addresses).
Indicative Timelines and Fees: Government fees, exchange rates, and review timelines fluctuate. Published figures represent historical averages or published baseline schedules and should not be treated as fixed quotes.
No Legal or Regulatory Certification: Platform outputs are informational search aids and do not constitute formal legal advice or regulatory endorsement.
Free Open Data Layer vs. Paid Consulting Services
Pure Global operates a dual model that separates its free public resources from its commercial consulting arm:
PURE GLOBAL: FREE VS. PAID SERVICES
| FREE OPEN DATA LAYER | PAID MARKET-ACCESS CONSULTING |
|---|---|
| (pureglobal.ai/resources) | (pureglobal.com) |
| • Searchable Databases & AI Tools | • Turnkey Dossier Preparation & Filing |
| • 37-Country AI Device Classifier | • In-Country Local Representation (LAR) |
| • Global Regulations Library | • Scope-based commercial engagements |
| • Checklists & Evidence Workpapers | • Multi-Country Submission Project Mgmt |
| • Public Regulatory News Feed | • Submission responses and maintenance |
Commercial services, scope, and pricing should be confirmed directly with Pure Global; they are separate from the free tools described in this guide.
Decision Rule: When to Use Free Tools vs. Engaging Professional Consultants
[REGULATORY TASK]
|
+-----------------+-----------------+
v v
[Discovery & Planning] [Submission & Filing]
| |
+--------------+--------------+ +--------------+--------------+
v v v v
Internal Triage, Indicative Budget Official Dossier In-Country Local
Predicate Search, & Timeline Drafting & Technical Representation &
Risk Scoping Benchmarking Filing Packages License Holding
| | | |
v v v v
+------------------+ +------------------+ +------------------+ +------------------+
| USE PURE GLOBAL | | USE PURE GLOBAL | | VERIFY PRIMARY | | ENGAGE LICENSED |
| FREE DATA LAYER | | FREE DATA LAYER | | SOURCES & ENGAGE | | REPRESENTATIVE |
| (pureglobal.ai) | | + PRIMARY SOURCES| | QUALIFIED COUNSEL| | OR CONSULTANCY |
+------------------+ +------------------+ +------------------+ +------------------+Use Free Data Tools When: Performing initial landscape research, identifying potential 510(k) predicates, comparing high-level regulatory lead times across markets, drafting internal compliance roadmaps, or staying updated on daily regulatory changes.
Verify Primary Sources When: Assembling official 510(k), De Novo, STED, or CE mark technical files; citing exact predicate indications for use; or calculating exact budget commitments for executive approval.
Engage Professional Consultants / Counsel When: Submitting formal regulatory dossiers, responding to Notified Bodies or national health authorities, appointing legally required in-country representatives, or managing complex clinical evaluation filings.
Frequently Asked Questions (FAQs)
Is Pure Global AI really free, and what is the catch?
Yes. The database searches, classifier, regulations library, checklists, and evidence workpapers listed in the Pure Global AI resource directory are presented as free resources. Commercial consulting and in-country representation are separate services.
Does Pure Global AI replace official regulator databases like FDA, EUDAMED, or NMPA?
No. Pure Global AI mirrors and indexes data from national health authorities, but it does not replace them. Submission-critical information—such as official clearance letters, active registration status, or legal device labeling—must always be verified directly against official primary sources like openFDA, EUDAMED, or NMPA.
Can I cite Pure Global AI search results directly in a 510(k), CE mark, or STED submission?
No. Regulatory submissions must cite primary official sources, official registration numbers, certified standards, and direct laboratory test reports. Pure Global AI should be used as a discovery and triage tool to identify those primary records, not as the cited primary evidence inside a technical dossier.
Why do record counts in Pure Global AI vary between the homepage, methodology table, and press reports?
Record counts depend on database definitions and refresh schedules. The homepage reports over 1.9 million device registrations, while the methodology page publishes separate country-level coverage figures that are not directly comparable. National registries may count device families, individual models, certificates, listings, or other record types differently. Use the figures to understand documented coverage—not to estimate market size or compare countries without normalizing the underlying record unit.
What is the difference between Pure Global AI's free tools and its paid consulting service?
Pure Global AI's free tools provide self-service search capabilities, data exploration, and compliance checklists. Pure Global's commercial services provide hands-on execution such as dossier support, regulatory strategy, local representative appointments, submission management, and health-authority communication. Scope and pricing depend on the engagement.
Summary and Key Takeaways
Pure Global AI combines two layers that should be governed differently: public-data research across national registries and evidence-first review of text supplied by the user. The first can shorten discovery; the second can expose gaps across risk, submission, quality, labeling, and post-market files. Neither layer replaces official records or accountable approval.
To maximize value while maintaining strict regulatory compliance, teams should adhere to three core principles:
Use the Right Tool for the Evidence: Use databases and research agents to retrieve public records; use one task-specific workpaper to review an authorized evidence pack.
Verify Against Primary Sources: Always cross-check critical clearance numbers, intended use statements, and establishment registration statuses against official government databases like openFDA or EUDAMED before finalizing regulatory filings.
Govern Controlled Records and Sensitive Inputs Separately: Use free checklists and workpapers for gap analysis, but execute formal audits, submissions, and technical-document approvals inside the manufacturer's controlled Quality Management System.
Used this way, the platform can reduce repetitive searching and make evidence gaps visible without confusing an AI-generated workpaper with a regulator decision, certified audit, or approved quality record.